Vipivotide tetraxetan (BioDeep_00000839806)
代谢物信息卡片
Vipivotide tetraxetan
化学式: C49H71N9O16 (1041.5018526)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CC(CCC1CNC(=O)CN2CCN(CCN(CCN(CC2)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(CC3=CC4=CC=CC=C4C=C3)C(=O)NCCCCC(C(=O)O)NC(=O)NC(CCC(=O)O)C(=O)O
InChI: InChI=1S/C49H71N9O16/c59-40(28-55-17-19-56(29-42(62)63)21-23-58(31-44(66)67)24-22-57(20-18-55)30-43(64)65)51-27-32-8-12-35(13-9-32)45(68)52-39(26-33-10-11-34-5-1-2-6-36(34)25-33)46(69)50-16-4-3-7-37(47(70)71)53-49(74)54-38(48(72)73)14-15-41(60)61/h1-2,5-6,10-11,25,32,35,37-39H,3-4,7-9,12-24,26-31H2,(H,50,69)(H,51,59)(H,52,68)(H,60,61)(H,62,63)(H,64,65)(H,66,67)(H,70,71)(H,72,73)(H2,53,54,74)/t32?,35?,37-,38-,39-/m0/s1
描述信息
D006401 - Hematologic Agents > D003029 - Coagulants > D007610 - Kallikreins
C308 - Immunotherapeutic Agent > C1512 - Immunoconjugate
C307 - Biological Agent
同义名列表
1 个代谢物同义名
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Florian Rosar, Felix Wenner, Fadi Khreish, Sebastian Dewes, Gudrun Wagenpfeil, Manuela A Hoffmann, Mathias Schreckenberger, Mark Bartholomä, Samer Ezziddin. Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy.
European journal of nuclear medicine and molecular imaging.
2022 04; 49(5):1584-1594. doi:
10.1007/s00259-021-05594-8. [PMID: 34725725] - Marco N Iannone, Stefano Stucchi, Elia A Turolla, Chiara Beretta, Samuele Ciceri, Clizia Chinello, Lisa Pagani, Sergio Todde, Patrizia Ferraboschi. Synthesis and automated fluorine-18 radiolabeling of new PSMA-617 derivatives with a CuAAC radiosynthetic approach.
Journal of labelled compounds & radiopharmaceuticals.
2022 03; 65(3):48-62. doi:
10.1002/jlcr.3959. [PMID: 34964165] - Ryota Imura, Atsuko Nakanishi Ozeki, Nanako Shida, Mika Kobayashi, Hiroyuki Ida, Youichiro Wada, Nobuyoshi Akimitsu, Yoshitaka Kumakura. Radiolabeling of PSMA-617 with 89Zr: A novel use of DMSO to improve radiochemical yield and preliminary small-animal PET results.
Nuclear medicine and biology.
2022 Mar; 106-107(?):21-28. doi:
10.1016/j.nucmedbio.2021.12.003. [PMID: 34998216] - Fadi Khreish, Zaidoon Ghazal, Robert J Marlowe, Florian Rosar, Amir Sabet, Stephan Maus, Johannes Linxweiler, Mark Bartholomä, Samer Ezziddin. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
European journal of nuclear medicine and molecular imaging.
2022 02; 49(3):1075-1085. doi:
10.1007/s00259-021-05525-7. [PMID: 34494131] - Guochang Wang, Haiyan Hong, Jie Zang, Qingxing Liu, Yuanyuan Jiang, Xinrong Fan, Zhaohui Zhu, Lin Zhu, Hank F Kung. Head-to-head comparison of [68 Ga]Ga-P16-093 and [68 Ga]Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients.
European journal of nuclear medicine and molecular imaging.
2022 02; 49(3):1052-1062. doi:
10.1007/s00259-021-05539-1. [PMID: 34557930] - Avik Chakraborty, Arpit Mitra, Megha Tawate, Sudip Sahoo, Sangita Lad, Sutapa Rakshit, Sujay Gaikwad, Sandip Basu, Hemant Shimpi, Sharmila Banerjee. Therapeutic Multidose Preparation of a Ready-to-Use 177Lu-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy.
Cancer biotherapy & radiopharmaceuticals.
2021 Oct; 36(8):682-692. doi:
10.1089/cbr.2020.4261. [PMID: 34402687] - Ugo De Giorgi, Maddalena Sansovini, Stefano Severi, Silvia Nicolini, Manuela Monti, Giorgia Gurioli, Flavia Foca, Chiara Casadei, Vincenza Conteduca, Monica Celli, Valentina Di Iorio, Daniele Calistri, Federica Matteucci, Finn Edler von Eyben, Gerhardt Attard, Giovanni Paganelli. Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial.
British journal of cancer.
2021 10; 125(9):1226-1232. doi:
10.1038/s41416-021-01508-5. [PMID: 34333554] - Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P Fendler, Ebrahim Delpassand. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312).
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2021 10; 62(10):1447-1456. doi:
10.2967/jnumed.121.262543. [PMID: 34272322] - Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P Fendler, Johannes Czernin. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2021 10; 62(10):1440-1446. doi:
10.2967/jnumed.121.261982. [PMID: 34016732] - Tim Wollenweber, Lucia Zisser, Elisabeth Kretschmer-Chott, Michael Weber, Bernhard Grubmüller, Gero Kramer, Shahrokh F Shariat, Markus Mitterhauser, Stefan Schmitl, Chrysoula Vraka, Alexander R Haug, Marcus Hacker, Markus Hartenbach, Sazan Rasul. Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer.
Current oncology (Toronto, Ont.).
2021 09; 28(5):3692-3704. doi:
10.3390/curroncol28050315. [PMID: 34590608] - Laura Meléndez-Alafort, Guillermina Ferro-Flores, Clara Santos-Cuevas, Blanca Ocampo-García, Sofia Turato, Giulio Fracasso, Cristina Bolzati, Antonio Rosato, Laura De Nardo. Preclinical dosimetric studies of 177 Lu-scFvD2B and comparison with 177 Lu-PSMA-617 and 177 Lu-iPSMA endoradiotherapeutic agents.
Medical physics.
2021 Jul; 48(7):4064-4074. doi:
10.1002/mp.14936. [PMID: 33966284] - Sebastian Martin, Roswitha Tönnesmann, Ina Hierlmeier, Stephan Maus, Florian Rosar, Juri Ruf, Jason P Holland, Samer Ezziddin, Mark D Bartholomä. Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [177Lu]Lu-PSMA-617.
Journal of medicinal chemistry.
2021 04; 64(8):4960-4971. doi:
10.1021/acs.jmedchem.1c00045. [PMID: 33826320] - Amanda Kristiansson, Anders Örbom, Jonas Ahlstedt, Helena Karlsson, Wahed Zedan, Magnus Gram, Bo Åkerström, Sven-Erik Strand, Mohamed Altai, Joanna Strand, Oskar Vilhelmsson Timmermand. 177Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α1-Microglobulin (A1M), Including Kidney Damage Assessment Using 99mTc-MAG3 Imaging.
Biomolecules.
2021 02; 11(2):. doi:
10.3390/biom11020263. [PMID: 33579037] - Mohini Guleria, Jeyachitra Amirdhanayagam, Haladhar D Sarma, Ramya Priya Rallapeta, V S Krishnamohan, Ajit Nimmagadda, Parthasarathy Ravi, Sailaja Patri, Tekchand Kalawat, Tapas Das. Preparation of 177Lu-PSMA-617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single-Vial Freeze-Dried PSMA-617 Kit Developed In-House.
BioMed research international.
2021; 2021(?):1555712. doi:
10.1155/2021/1555712. [PMID: 34845436] - Florian Rosar, Fabian Hau, Mark Bartholomä, Stephan Maus, Tobias Stemler, Johannes Linxweiler, Samer Ezziddin, Fadi Khreish. Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy.
Theranostics.
2021; 11(9):4050-4060. doi:
10.7150/thno.56211. [PMID: 33754047] - Giovanni Paganelli, Anna Sarnelli, Stefano Severi, Maddalena Sansovini, Maria Luisa Belli, Manuela Monti, Flavia Foca, Monica Celli, Silvia Nicolini, Elisa Tardelli, Irene Marini, Federica Matteucci, Melchiore Giganti, Valentina Di Iorio, Ugo De Giorgi. Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients.
European journal of nuclear medicine and molecular imaging.
2020 12; 47(13):3008-3017. doi:
10.1007/s00259-020-04856-1. [PMID: 32430583] - Robert Seifert, Katharina Kessel, Katrin Schlack, Matthias Weckesser, Martin Bögemann, Kambiz Rahbar. Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis.
European journal of nuclear medicine and molecular imaging.
2020 08; 47(9):2106-2112. doi:
10.1007/s00259-020-04703-3. [PMID: 32062682] - Maria Luisa Belli, Emilio Mezzenga, Valentina Di Iorio, Monica Celli, Paola Caroli, Elisabeth Canali, Federica Matteucci, Elisa Tardelli, Ilaria Grassi, Maddalena Sansovini, Silvia Nicolini, Stefano Severi, Marta Cremonesi, Mahila Ferrari, Giovanni Paganelli, Anna Sarnelli. A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods.
Journal of visualized experiments : JoVE.
2020 04; ?(158):. doi:
10.3791/60477. [PMID: 32391816] - Xinyue Yao, Zhihao Zha, Karl Ploessl, Seok Rye Choi, Ruiyue Zhao, David Alexoff, Lin Zhu, Hank F Kung. Synthesis and evaluation of novel radioiodinated PSMA targeting ligands for potential radiotherapy of prostate cancer.
Bioorganic & medicinal chemistry.
2020 03; 28(5):115319. doi:
10.1016/j.bmc.2020.115319. [PMID: 32001090] - Andreea D Stuparu, Catherine A L Meyer, Susan L Evans-Axelsson, Katharina Lückerath, Liu H Wei, Woosuk Kim, Soumya Poddar, Christine E Mona, Magnus Dahlbom, Mark D Girgis, Caius G Radu, Johannes Czernin, Roger Slavik. Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study.
Theranostics.
2020; 10(6):2612-2620. doi:
10.7150/thno.42228. [PMID: 32194823] - Sonam Suman, Rahul V Parghane, Amit Joshi, Kumar Prabhash, Ganesh Bakshi, Sanjay Talole, Sharmila Banerjee, Sandip Basu. Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort.
The British journal of radiology.
2019 Dec; 92(1104):20190380. doi:
10.1259/bjr.20190380. [PMID: 31600089] - Jingjing Zhang, Harshad R Kulkarni, Aviral Singh, Christiane Schuchardt, Karin Niepsch, Thomas Langbein, Richard P Baum. 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2019 11; 60(11):1579-1586. doi:
10.2967/jnumed.118.223149. [PMID: 30850499] - Sebastian Hoberück, Gerd Wunderlich, Enrico Michler, Tobias Hölscher, Martin Walther, Danilo Seppelt, Ivan Platzek, Klaus Zöphel, Jörg Kotzerke. Dual-time-point 64 Cu-PSMA-617-PET/CT in patients suffering from prostate cancer.
Journal of labelled compounds & radiopharmaceuticals.
2019 Jun; 62(8):523-532. doi:
10.1002/jlcr.3745. [PMID: 31042811] - Hendrik Rathke, Paul Flechsig, Walter Mier, Marcus Bronzel, Eleni Mavriopoulou, Markus Hohenfellner, Frederik Lars Giesel, Uwe Haberkorn, Clemens Kratochwil. Dosimetry Estimate and Initial Clinical Experience with 90Y-PSMA-617.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2019 Jun; 60(6):806-811. doi:
10.2967/jnumed.118.218917. [PMID: 30389816] - John Violet, Price Jackson, Justin Ferdinandus, Shahneen Sandhu, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Sue Ping Thang, Peter Eu, Mark Scalzo, Declan Murphy, Scott Williams, Rodney J Hicks, Michael S Hofman. Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2019 04; 60(4):517-523. doi:
10.2967/jnumed.118.219352. [PMID: 30291192] - Anna Sarnelli, Maria Luisa Belli, Valentina Di Iorio, Emilio Mezzenga, Monica Celli, Stefano Severi, Elisa Tardelli, Silvia Nicolini, Devil Oboldi, Licia Uccelli, Corrado Cittanti, Manuela Monti, Mahila Ferrari, Giovanni Paganelli. Dosimetry of 177Lu-PSMA-617 after Mannitol Infusion and Glutamate Tablet Administration: Preliminary Results of EUDRACT/RSO 2016-002732-32 IRST Protocol.
Molecules (Basel, Switzerland).
2019 Feb; 24(3):. doi:
10.3390/molecules24030621. [PMID: 30754620] - Mike Sathekge, Frank Bruchertseifer, Otto Knoesen, Florette Reyneke, Ismaheel Lawal, Thabo Lengana, Cindy Davis, Johncy Mahapane, Ceceila Corbett, Mariza Vorster, Alfred Morgenstern. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.
European journal of nuclear medicine and molecular imaging.
2019 01; 46(1):129-138. doi:
10.1007/s00259-018-4167-0. [PMID: 30232539] - Francesco Cantiello, Fabio Crocerossa, Giorgio Ivan Russo, Vincenzo Gangemi, Matteo Ferro, Mihai Dorin Vartolomei, Giuseppe Lucarelli, Maria Mirabelli, Chiara Scafuro, Giuseppe Ucciero, Ottavio De Cobelli, Giuseppe Morgia, Rocco Damiano, Giuseppe Lucio Cascini. Comparison Between 64Cu-PSMA-617 PET/CT and 18F-Choline PET/CT Imaging in Early Diagnosis of Prostate Cancer Biochemical Recurrence.
Clinical genitourinary cancer.
2018 10; 16(5):385-391. doi:
10.1016/j.clgc.2018.05.014. [PMID: 29937067] - Anna Yordanova, Anja Becker, Elisabeth Eppard, Stefan Kürpig, Christian Fisang, Georg Feldmann, Markus Essler, Hojjat Ahmadzadehfar. The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer.
European journal of nuclear medicine and molecular imaging.
2017 Aug; 44(9):1473-1479. doi:
10.1007/s00259-017-3681-9. [PMID: 28337529] - Clemens Kratochwil, Frederik L Giesel, Melsa Stefanova, Martina Benešová, Marcus Bronzel, Ali Afshar-Oromieh, Walter Mier, Matthias Eder, Klaus Kopka, Uwe Haberkorn. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2016 Aug; 57(8):1170-6. doi:
10.2967/jnumed.115.171397. [PMID: 26985056] - Ali Afshar-Oromieh, Henrik Hetzheim, Clemens Kratochwil, Martina Benesova, Matthias Eder, Oliver C Neels, Michael Eisenhut, Wolfgang Kübler, Tim Holland-Letz, Frederik L Giesel, Walter Mier, Klaus Kopka, Uwe Haberkorn. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2015 Nov; 56(11):1697-705. doi:
10.2967/jnumed.115.161299. [PMID: 26294298]